Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial
Nanna M, Doan Q, Fabricatore A, Faurby M, Henry A, Houshmand‐Oeregaard A, Levine A, Navar A, Sforzolini T, Toliver J. Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial. Diabetes Obesity And Metabolism 2025, 27: 3442-3452. PMID: 40183412, PMCID: PMC12046440, DOI: 10.1111/dom.16370.Peer-Reviewed Original ResearchConceptsHeart disease eventsRisk of heart diseaseUS adultsDisease eventsFood and Drug AdministrationImpact of semaglutideMedical careNational Health and Nutrition Examination Survey dataHeart diseaseNutrition Examination Survey dataPopulation-based prediction modelSurvey of US adultsCardiovascular diseaseRisk of heart attackFood and Drug Administration indicationsUnited StatesPopulation-level impactUS Food and Drug AdministrationRecurrent CV eventsTrial of patientsAdverse cardiovascular eventsType 2 diabetesAtherosclerotic cardiovascular diseaseHazard ratioInclusion criteria
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply